Dr. Veerapol Khemarangsan, Chief Executive Officer of MEDEZE Group Public Company Limited (SET: MEDEZE), celebrated the company’s 15th anniversary under the theme “MEDEZE 15th Anniversary: Future of Thailand HEALTH Economy.”
This milestone underscores the company’s longstanding strength and unwavering commitment to innovation in stem cell technology over the past 15 years. Dr. Veerapol emphasized that MEDEZE’s journey reflects its relentless efforts in developing cutting-edge stem cell solutions, winning ongoing trust from clients who use its international-standard storage and consulting services powered by high-efficiency, advanced technologies.
Looking ahead to the end of 2025, MEDEZE is pushing forward with continuous innovation for the next generation of healthcare, reaffirming its status as a leader in advanced medical technology.
The company positions itself as a vital force in modernizing Thailand’s healthcare ecosystem to international standards, supporting the Thai medical economy, which is internationally lauded for both medical staff competency and state-of-the-art healthcare services.
Coupled with Thailand’s established role as a leading medical tourism destination, MEDEZE is working to drive the HEALTH Economy as a high-value, high-potential economic engine that is set to shape the future of Thailand’s medical sector.
A significant recent development for MEDEZE is its collaboration with Vachira Phuket Hospital and the Bang Rak Medical Center of the Department of Disease Control to spearhead the Advanced Therapy Medicinal Products Sandbox (ATMPs Sandbox) project. This marks a pivotal starting point after the Ministry of Public Health placed renewed emphasis and support on ATMPs.
MEDEZE is actively involved in the refurbishment of the Bang Rak Medical Center building to establish the sandbox headquarters and dedicated laboratories for ongoing research, experimental monitoring, and compliance with ethical standards set by the Ministry’s Human Research Ethics Committee. Patients will be enrolled on a strict “First Come, First Served” basis once they meet all required criteria.
MEDEZE has set clear targets: to conduct research on at least two diseases and register advanced therapies for two to three conditions each year. The company is currently applying for approval to treat skin diseases, anti-aging conditions, and kidney failure.
Looking to the future, the pipeline may expand to include autoimmune diseases such as SLE, psoriasis, and cirrhosis. Stem cell therapy is positioned as a solution for all degenerative, inflammatory, and allergic disorders.
